Oncor bladder cancer test trial to begin in late summer, JHU researcher says.
This article was originally published in The Gray Sheet
Executive SummaryONCOR BLADDER CANCER DIAGNOSTIC CLINICAL TRIAL TO BEGIN AT JOHNS HOPKINS in the late summer to assess the utility of a new molecular diagnostic test, according to Johns Hopkins University investigator David Sidransky, who developed the test. Under the direction of JHU principal investigator Mark Schoenberg, the Phase II/III trial will enroll 300 patients and assess whether the test can diagnose bladder cancer earlier than the standard diagnostic procedures -- cytology, or testing cancer cells in the urine, and cystoscopy.
You may also be interested in...
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.